References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
- Latagliata R, Breccia M, Carmosino I, et al. “Real-life” results of front-line treatment with imatinib in older patients (>/= 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34(11):1472–1475.
- Sun T, Wang S, Sun H, et al. Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leuk Lymphoma. 2018 Jan;59(1):49-58.
- Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31(9):1915–1921.
- Arnieri B, Bernaards C, Wilhelm K, et al. Changing demographics and treatment patterns in patients the United States with chronic lymphocytic leukemia in the first-line setting as assessed using a novel electronic health record database. Blood. 2016;128(22):4787.
- Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166–174.
- Saret CJ, Winn AN, Shah G, et al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015;125(12):1866–1869.
- Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 2015;121(19):3372–3379.
- Schey S, Montero LFC, Stengel-Tosetti C, et al. The cost impact of lenalidomide for newly diagnosed multiple myeloma in the EU5. Oncol Ther. 2017;5(1):31–40.
- Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18(1):37–45.
- Kaul S, Avila JC, Mehta HB, et al. Cost-related medication nonadherence among adolescent and young adult cancer survivors. Cancer. 2017;123(14):2726–2734.
- Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016;34(36):4323–4328.
- Sargent DJ, Shi Q, Flowers CR, et al. The search for surrogate endpoints in trials in diffuse large B-cell lymphoma: the surrogate endpoints for aggressive lymphoma project. Oncologist. 2017;22:1415–1418.
- Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003.
- Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treatment. 2015;2015:982395.
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934.
- Rocque G, Blayney DW, Jahanzeb M, et al. Choosing wisely in oncology: are we ready for value-based care? J Oncol Pract. 2017;11:e935-e943.
- Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;1–10.
- Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1(9):1293–1300.
- Bentley TGK, Cohen JT, Elkin EB, et al. Measuring the value of new drugs: validity and reliability of 4 value assessment frameworks in the oncology setting. J Manag Care Spec Pharm. 2017;23(6–a Suppl):S34–S48.